These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 20525919)

  • 41. A clofarabine-based bridging regimen in patients with relapsed ALL and persistent minimal residual disease (MRD).
    Gossai N; Verneris MR; Karras NA; Gorman MF; Patel NJ; Burke MJ
    Bone Marrow Transplant; 2014 Mar; 49(3):440-2. PubMed ID: 24317126
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A multi-center phase I study of clofarabine, etoposide and cyclophosphamide in combination in pediatric patients with refractory or relapsed acute leukemia.
    Hijiya N; Gaynon P; Barry E; Silverman L; Thomson B; Chu R; Cooper T; Kadota R; Rytting M; Steinherz P; Shen V; Jeha S; Abichandani R; Carroll WL
    Leukemia; 2009 Dec; 23(12):2259-64. PubMed ID: 19741725
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Population pharmacokinetics of treosulfan in paediatric patients undergoing hematopoietic stem cell transplantation.
    van der Stoep MYEC; Zwaveling J; Bertaina A; Locatelli F; Guchelaar HJ; Lankester AC; Moes DJAR
    Br J Clin Pharmacol; 2019 Sep; 85(9):2033-2044. PubMed ID: 31144349
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Early UK experience in the use of clofarabine in the treatment of relapsed and refractory paediatric acute lymphoblastic leukaemia.
    O'Connor D; Sibson K; Caswell M; Connor P; Cummins M; Mitchell C; Motwani J; Taj M; Vora A; Wynn R; Kearns PR
    Br J Haematol; 2011 Aug; 154(4):482-5. PubMed ID: 21689087
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pharmacokinetics of alemtuzumab in pediatric patients undergoing ex vivo T-cell-depleted haploidentical hematopoietic cell transplantation.
    Bhoopalan SV; Cross SJ; Panetta JC; Triplett BM
    Cancer Chemother Pharmacol; 2020 Dec; 86(6):711-717. PubMed ID: 33037919
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effect of hemodialysis on the plasma levels of clofarabine.
    Steinherz PG; Shukla N; Kobos R; Latcha S
    Pediatr Blood Cancer; 2010 Jul; 55(1):196-8. PubMed ID: 20232428
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Control of relapsed or refractory acute myeloid leukemia by clofarabine in preparation for allogeneic stem cell transplant.
    Loeffler C; Kapp M; Grigoleit GU; Mielke S; Loeffler J; Heuschmann PU; Malzahn U; Hupp E; Einsele H; Stuhler G
    Leuk Lymphoma; 2015; 56(12):3365-9. PubMed ID: 26014275
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The role of Clofarabine in the treatment of adults with acute myeloid leukemia.
    Fozza C
    Crit Rev Oncol Hematol; 2015 Mar; 93(3):237-45. PubMed ID: 25457773
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Combination of clofarabine, cyclophosphamide, and etoposide for relapsed or refractory childhood and adolescent acute myeloid leukemia.
    Messinger Y; Boklan J; Goldberg J; DuBois SG; Oesterheld J; Abla O; Martin A; Weinstein J; Hijiya N
    Pediatr Hematol Oncol; 2017 May; 34(4):187-198. PubMed ID: 29039989
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Allo-SCT conditioning for myelodysplastic syndrome and acute myeloid leukemia with clofarabine, cytarabine and ATG.
    Martin MG; Uy GL; Procknow E; Stockerl-Goldstein K; Cashen A; Westervelt P; Abboud CN; Augustin K; Luo J; DiPersio JF; Vij R
    Bone Marrow Transplant; 2009 Jul; 44(1):13-7. PubMed ID: 19139740
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Phase II Trial of Reduced-Intensity Busulfan/Clofarabine Conditioning with Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Acute Myeloid Leukemia, Myelodysplastic Syndromes, and Acute Lymphoid Leukemia.
    El-Jawahri A; Li S; Ballen KK; Cutler C; Dey BR; Driscoll J; Hunnewell C; Ho VT; McAfee SL; Poliquin C; Saylor M; Soiffer RJ; Spitzer TR; Alyea E; Chen YB
    Biol Blood Marrow Transplant; 2016 Jan; 22(1):80-5. PubMed ID: 26260679
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A randomized phase 2 study of idarubicin and cytarabine with clofarabine or fludarabine in patients with newly diagnosed acute myeloid leukemia.
    Jabbour E; Short NJ; Ravandi F; Huang X; Xiao L; Garcia-Manero G; Plunkett W; Gandhi V; Sasaki K; Pemmaraju N; Daver NG; Borthakur G; Jain N; Konopleva M; Estrov Z; Kadia TM; Wierda WG; DiNardo CD; Brandt M; O'Brien SM; Cortes JE; Kantarjian H
    Cancer; 2017 Nov; 123(22):4430-4439. PubMed ID: 28708931
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A phase I dose-escalation study of clofarabine in combination with fractionated gemtuzumab ozogamicin in patients with refractory or relapsed acute myeloid leukemia.
    Foster MC; Amin C; Voorhees PM; van Deventer HW; Richards KL; Ivanova A; Whitman J; Chiu WM; Barr ND; Shea T
    Leuk Lymphoma; 2012 Jul; 53(7):1331-7. PubMed ID: 22149206
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Clofarabine, cyclophosphamide and etoposide as single-course re-induction therapy for children with refractory/multiple relapsed acute lymphoblastic leukaemia.
    Locatelli F; Testi AM; Bernardo ME; Rizzari C; Bertaina A; Merli P; Pession A; Giraldi E; Parasole R; Barberi W; Zecca M
    Br J Haematol; 2009 Nov; 147(3):371-8. PubMed ID: 19747360
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Long-Term Follow-Up and Impact of Comorbidity before Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Relapsed or Refractory Acute Myeloid Leukemia-Lessons Learned from the Prospective BRIDGE Trial.
    Middeke JM; Herbst R; Parmentier S; Bug G; Hänel M; Stuhler G; Schäfer-Eckart K; Rösler W; Klein S; Bethge W; Bitz U; Büttner B; Knoth H; Alakel N; Schaich M; Morgner A; Kramer M; Sockel K; von Bonin M; Stölzel F; Platzbecker U; Röllig C; Thiede C; Ehninger G; Bornhäuser M; Schetelig J
    Biol Blood Marrow Transplant; 2017 Sep; 23(9):1491-1497. PubMed ID: 28527985
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Clofarabine combinations as acute myeloid leukemia salvage therapy.
    Faderl S; Ferrajoli A; Wierda W; Huang X; Verstovsek S; Ravandi F; Estrov Z; Borthakur G; Kwari M; Kantarjian HM
    Cancer; 2008 Oct; 113(8):2090-6. PubMed ID: 18756533
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Long-Term Outcomes after Treatment with Clofarabine ± Fludarabine with Once-Daily Intravenous Busulfan as Pretransplant Conditioning Therapy for Advanced Myeloid Leukemia and Myelodysplastic Syndrome.
    Alatrash G; Thall PF; Valdez BC; Fox PS; Ning J; Garber HR; Janbey S; Worth LL; Popat U; Hosing C; Alousi AM; Kebriaei P; Shpall EJ; Jones RB; de Lima M; Rondon G; Chen J; Champlin RE; Andersson BS
    Biol Blood Marrow Transplant; 2016 Oct; 22(10):1792-1800. PubMed ID: 27377901
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pharmacokinetics and pharmacodynamics of plasma clofarabine and cellular clofarabine triphosphate in patients with acute leukemias.
    Gandhi V; Kantarjian H; Faderl S; Bonate P; Du M; Ayres M; Rios MB; Keating MJ; Plunkett W
    Clin Cancer Res; 2003 Dec; 9(17):6335-42. PubMed ID: 14695132
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Clofarabine as a novel nucleoside analogue approved to treat patients with haematological malignancies: mechanism of action and clinical activity.
    Lech-Maranda E; Korycka A; Robak T
    Mini Rev Med Chem; 2009 Jun; 9(7):805-12. PubMed ID: 19519505
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Phase I dose-escalation trial of clofarabine followed by escalating doses of fractionated cyclophosphamide in children with relapsed or refractory acute leukemias.
    Abd Elmoneim A; Gore L; Ricklis RM; Boklan J; Cooper T; Narendran A; Rolla K; Scott T; Arceci RJ
    Pediatr Blood Cancer; 2012 Dec; 59(7):1252-8. PubMed ID: 22887831
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.